Humira and the Looming Biosimilar Boom
A wave of FDA-approved biosimilars for Humira and other costly biologics will enter the U.S. market in 2023. What does it mean for patients, payers and plan designs?
Menu
Specialty Copay Programs – Accumulate, Maximize or Avoid?
Utilization of specialty medications continues to rise, and so do costs for patients and plan sponsors. Thanks to these rising costs, we see more plans choosing to implement copay adjustment programs, but it’s crucial to understand how they fit into your benefit and where they improve or hinder your plan.
On One Condition – Alzheimer’s Disease
Each month, our pharmacists share clinical insights, market trends and real-life savings examples specific to some of the most common conditions. This month we take a look at Alzheimer’s Disease.
